175 related articles for article (PubMed ID: 31653903)
21. Matrix metalloproteinase 9 targeting peptides: syntheses, 68Ga-labeling, and preliminary evaluation in a rat melanoma xenograft model.
Ujula T; Huttunen M; Luoto P; Peräkylä H; Simpura I; Wilson I; Bergman M; Roivainen A
Bioconjug Chem; 2010 Sep; 21(9):1612-21. PubMed ID: 20795647
[TBL] [Abstract][Full Text] [Related]
22. Development of a New Class of CXCR4-Targeting Radioligands Based on the Endogenous Antagonist EPI-X4 for Oncological Applications.
Gaonkar RH; Schmidt YT; Mansi R; Almeida-Hernandez Y; Sanchez-Garcia E; Harms M; Münch J; Fani M
J Med Chem; 2023 Jul; 66(13):8484-8497. PubMed ID: 37328158
[TBL] [Abstract][Full Text] [Related]
23. Population Pharmacokinetic and Pharmacodynamic Modeling of LY2510924 in Patients With Advanced Cancer.
Bihorel S; Raddad E; Fiedler-Kelly J; Stille JR; Hing J; Ludwig E
CPT Pharmacometrics Syst Pharmacol; 2017 Sep; 6(9):614-624. PubMed ID: 28643374
[TBL] [Abstract][Full Text] [Related]
24. Preclinical evaluation of a CXCR4-specific (68)Ga-labelled TN14003 derivative for cancer PET imaging.
George GP; Stevens E; Åberg O; Nguyen QD; Pisaneschi F; Spivey AC; Aboagye EO
Bioorg Med Chem; 2014 Jan; 22(2):796-803. PubMed ID: 24365390
[TBL] [Abstract][Full Text] [Related]
25. Positron emission tomography imaging of tumors expressing the human chemokine receptor CXCR4 in mice with the use of 64Cu-AMD3100.
Weiss ID; Jacobson O; Kiesewetter DO; Jacobus JP; Szajek LP; Chen X; Farber JM
Mol Imaging Biol; 2012 Feb; 14(1):106-14. PubMed ID: 21347799
[TBL] [Abstract][Full Text] [Related]
26. PET imaging of CXCR4 receptors in cancer by a new optimized ligand.
Demmer O; Gourni E; Schumacher U; Kessler H; Wester HJ
ChemMedChem; 2011 Oct; 6(10):1789-91. PubMed ID: 21780290
[No Abstract] [Full Text] [Related]
27. Structural characterization and in vivo evaluation of β-Hairpin peptidomimetics as specific CXCR4 imaging agents.
Lesniak WG; Sikorska E; Shallal H; Behnam Azad B; Lisok A; Pullambhatla M; Pomper MG; Nimmagadda S
Mol Pharm; 2015 Mar; 12(3):941-53. PubMed ID: 25590535
[TBL] [Abstract][Full Text] [Related]
28. Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography.
Nimmagadda S; Pullambhatla M; Stone K; Green G; Bhujwalla ZM; Pomper MG
Cancer Res; 2010 May; 70(10):3935-44. PubMed ID: 20460522
[TBL] [Abstract][Full Text] [Related]
29. N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imaging.
Gourni E; Mansi R; Jamous M; Waser B; Smerling C; Burian A; Buchegger F; Reubi JC; Maecke HR
J Nucl Med; 2014 Oct; 55(10):1719-25. PubMed ID: 25146125
[TBL] [Abstract][Full Text] [Related]
30. Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics.
Kumar P; Tripathi SK; Chen CP; Wickstrom E; Thakur ML
Mol Imaging Biol; 2019 Feb; 21(1):130-139. PubMed ID: 29802552
[TBL] [Abstract][Full Text] [Related]
31. Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor.
Herrmann K; Lapa C; Wester HJ; Schottelius M; Schiepers C; Eberlein U; Bluemel C; Keller U; Knop S; Kropf S; Schirbel A; Buck AK; Lassmann M
J Nucl Med; 2015 Mar; 56(3):410-6. PubMed ID: 25698782
[TBL] [Abstract][Full Text] [Related]
32. Advances in PET Imaging of the CXCR4 Receptor: [
Lindenberg L; Ahlman M; Lin F; Mena E; Choyke P
Semin Nucl Med; 2024 Jan; 54(1):163-170. PubMed ID: 37923671
[TBL] [Abstract][Full Text] [Related]
33. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical.
Lopez-Rodriguez V; Gaspar-Carcamo RE; Pedraza-Lopez M; Rojas-Calderon EL; Arteaga de Murphy C; Ferro-Flores G; Avila-Rodriguez MA
Nucl Med Biol; 2015 Feb; 42(2):109-14. PubMed ID: 25316595
[TBL] [Abstract][Full Text] [Related]
34. A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer.
Galsky MD; Vogelzang NJ; Conkling P; Raddad E; Polzer J; Roberson S; Stille JR; Saleh M; Thornton D
Clin Cancer Res; 2014 Jul; 20(13):3581-8. PubMed ID: 24727324
[TBL] [Abstract][Full Text] [Related]
35. Tumor Targeting via Sialic Acid: [
Tsoukalas C; Geninatti-Crich S; Gaitanis A; Tsotakos T; Paravatou-Petsotas M; Aime S; Jiménez-Juárez R; Anagnostopoulos CD; Djanashvili K; Bouziotis P
Mol Imaging Biol; 2018 Oct; 20(5):798-807. PubMed ID: 29464496
[TBL] [Abstract][Full Text] [Related]
36. Comparative Evaluation of Using NOTA and DOTA Derivatives as Bifunctional Chelating Agents in the Preparation of
Guleria M; Das T; Amirdhanayagam J; Sarma HD; Dash A
Cancer Biother Radiopharm; 2018 Feb; 33(1):8-16. PubMed ID: 29373046
[TBL] [Abstract][Full Text] [Related]
37. Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.
Salgia R; Weaver RW; McCleod M; Stille JR; Yan SB; Roberson S; Polzer J; Flynt A; Raddad E; Peek VL; Wijayawardana SR; Um SL; Gross S; Connelly MC; Morano C; Repollet M; Sanders R; Baeten K; D'Haese D; Spigel DR
Invest New Drugs; 2017 Jun; 35(3):334-344. PubMed ID: 28299514
[TBL] [Abstract][Full Text] [Related]
38. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
39. Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors.
Hanaoka H; Mukai T; Tamamura H; Mori T; Ishino S; Ogawa K; Iida Y; Doi R; Fujii N; Saji H
Nucl Med Biol; 2006 May; 33(4):489-94. PubMed ID: 16720240
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and in vitro evaluation of 68Ga-DOTA-4-FBn-TN14003, a novel tracer for the imaging of CXCR4 expression.
Hennrich U; Seyler L; Schäfer M; Bauder-Wüst U; Eisenhut M; Semmler W; Bäuerle T
Bioorg Med Chem; 2012 Feb; 20(4):1502-10. PubMed ID: 22264762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
